Canada’s biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.
Looking ahead into 2024, some market participants expect to see more investor interest in biotech as a variety of trends take hold — those include a greater focus on personalized medicine, cancer immunotherapies and more.
Against that backdrop, which Canadian biotech stocks are performing the best? Below the Investing News Network outlines the three TSX-listed biotech stocks have seen the biggest gains year-on-year. Data was gathered on January 18, 2024, using TradingView’s stock screener, and companies listed had market caps above C$50 million at that time.
Both TSX and TSXV stocks were considered, but no TSXV companies made the list this time.
1. Antibe Therapeutics (TSX:ATE)
Year-on-year gain: 41.79 percent; market cap: C$53.69 million; share price: C$0.95
Antibe Therapeutics is focused on…
